Sign In
Buy CSTL
$20.39
+0.680 (+3.45%)
At Close: Jun 03, 2026
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates
06:46pm, Monday, 05'th Aug 2024
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.70 per share a year
Castle Biosciences Reports Second Quarter 2024 Results
04:05pm, Monday, 05'th Aug 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the second quarter and six months ended June 30, 2024.
Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know
11:06am, Monday, 29'th Jul 2024
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
07:00am, Monday, 22'nd Jul 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences and skin cancer survivor Teddi Mellencamp Arroyave launch campaign aimed at empowering patients impacted by melanoma.
All You Need to Know About Castle Biosciences (CSTL) Rating Upgrade to Strong Buy
01:01pm, Friday, 12'th Jul 2024
Castle Biosciences (CSTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Castle Biosciences Honored with Top Workplaces Awards
07:00am, Thursday, 11'th Jul 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle honored as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Exce
Top 5 Health Care Stocks That May Explode In July
08:40am, Monday, 08'th Jul 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AGA--The latest AGA clinical practice guideline acknowledges the role that TissueCypher can play identifying high-risk Barrett's esophagus patients.
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
09:25am, Friday, 21'st Jun 2024
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 20'th Jun 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4).
Castle Biosciences' Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
04:30pm, Friday, 14'th Jun 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's founder, president & CEO, Derek Maetzold, has been named an EY 2024 Entrepreneur Of The Year® for the Gulf South region.
Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year?
11:20am, Thursday, 13'th Jun 2024
Here is how Castle Biosciences, Inc. (CSTL) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASCO--Castle will present new data related to its DecisionDx-Melanoma and DecisionDx-UM tests at the 2024 ASCO Annual Meeting, May 31-June 4, 2024.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of a study demonstrating the impact of the DecisionDx-SCC test in guiding adjuvant radiation therapy decision-maki
Does Castle Biosciences (CSTL) Have the Potential to Rally 36.15% as Wall Street Analysts Expect?
10:56am, Thursday, 23'rd May 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable,
